Cargando…

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β(2)-agonists in patients with atopic asthma

OBJECTIVES: To evaluate the efficacy and safety of AZD1981, a potent, specific antagonist of the CRTh2 receptor, as add-on therapy to inhaled corticosteroids (ICS) and long-acting β(2)-agonists (LABA), in patients with persistent asthma with an allergic component. PATIENTS AND METHODS: In this place...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bateman, Eric D, O’Brien, Christopher, Rugman, Paul, Luke, Sally, Ivanov, Stefan, Uddin, Mohib
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942163/ https://www.ncbi.nlm.nih.gov/pubmed/29765200 http://dx.doi.org/10.2147/DDDT.S147389

Ejemplares similares

Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
por: Kuna, Piotr, et al.
Publicado: (2016)

CRTH2 antagonists in asthma: current perspectives
por: Singh, Dave, et al.
Publicado: (2017)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans
por: Hoch, Matthias, et al.
Publicado: (2013)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

CRTH2 expression on T cells in asthma
por: Mutalithas, K, et al.
Publicado: (2010)

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
por: Erpenbeck, Veit J., et al.
Publicado: (2016)

CRTH2: a potential target for the treatment of organ fibrosis: CRTH2 is a potential target for organ fibrosis
por: Fan, Sisi, et al.
Publicado: (2022)

CRTH2 in Pulmonary Fibrosis: Friend or Foe?
por: He, Chao, et al.
Publicado: (2022)

Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
por: Delaney, Stephen, et al.
Publicado: (2016)

Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review
por: Kankaanranta, Hannu, et al.
Publicado: (2004)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
por: Lim, Emerson A., et al.
Publicado: (2022)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
por: Alakeel, Yousif S., et al.
Publicado: (2022)

Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults
por: Altawalbeh, Shoroq M., et al.
Publicado: (2018)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
por: Rottenkolber, Marietta, et al.
Publicado: (2015)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

The impact of CRTH2 antagonist OC 000459 on pulmonary function of asthma patients: a meta-analysis of randomized controlled trials
por: Tang, Meng, et al.
Publicado: (2020)

The therapeutic potential of CRTH2/DP2 beyond allergy and asthma
por: Jandl, Katharina, et al.
Publicado: (2017)

Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects
por: Singh, Dave, et al.
Publicado: (2015)

Inhaled Corticosteroids
por: Barnes, Peter J.
Publicado: (2010)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

A CRTH2 antagonist, CT-133, suppresses NF-κB signalling to relieve lipopolysaccharide-induced acute lung injury
por: Hussain, Musaddique, et al.
Publicado: (2019)

Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonists in asthma: a systematic review and meta-analysis protocol
por: Liu, Wei, et al.
Publicado: (2018)

Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
por: Lötvall, Jan, et al.
Publicado: (2014)

Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D(2)
por: Nagata, Nanae, et al.
Publicado: (2017)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Comparison of 12-Week Additional Effect Features of Formoterol Co-Inhalation and Tulobuterol Patch on Budesonide Inhalation in Elderly Patients With Asthma
por: Fukahori, Susumu, et al.
Publicado: (2020)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

Bacterial lysate add‐on therapy to reduce exacerbations in severe asthma: A double‐blind placebo‐controlled trial
por: de Boer, Geertje M., et al.
Publicado: (2021)

Low adherence to inhaled corticosteroids/long-acting β(2)-agonists and biologic treatment in severe asthmatics
por: Caminati, Marco, et al.
Publicado: (2020)

Effects of Add-On Therapy with NDC-052, an Extract from Magnoliae Flos, in Adult Asthmatic Patients Receiving Inhaled Corticosteroids
por: Park, Chan Sun, et al.
Publicado: (2012)

Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
por: Rudulier, Christopher D., et al.
Publicado: (2019)

Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis
por: Goldstein, Debra A., et al.
Publicado: (2016)

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?
por: Maes, Tania, et al.
Publicado: (2020)

Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice
por: Chen, Guilin, et al.
Publicado: (2018)

Asthma diagnosis and treatment – 1018. Effect of inhaled corticosteroids with long-acting beta2 agonists vs. inhaled corticosteroids alone on asthma control in children: results from national ashtma survey
por: Lockey, Richard F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gg09r4m365b9le21hi3tpjnqfc